| P50 | author | Lesley J Scott | Q62563724 |
| P2093 | author name string | Mark Sanford | |
| P2860 | cites work | Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia | Q22241430 |
| | Chlorpromazine: unlocking psychosis | Q22242093 |
| | Benzodiazepines for psychosis-induced aggression or agitation | Q24245821 |
| | Benzodiazepines for schizophrenia | Q24246319 |
| | An overview of psychotropic drug-drug interactions | Q28270894 |
| | Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations | Q33285595 |
| | A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients | Q33288884 |
| | Size of burden of schizophrenia and psychotic disorders | Q33341221 |
| | The pathophysiology of agitation | Q34128651 |
| | Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. | Q34312597 |
| | Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder | Q34333899 |
| | Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia | Q34383654 |
| | Pharmacological management of acute agitation | Q34421338 |
| | Aripiprazole: pharmacology, efficacy, safety and tolerability | Q34558285 |
| | Lifetime prevalence of psychotic and bipolar I disorders in a general population | Q34596831 |
| | Schizophrenia and suicide: systematic review of risk factors | Q36182528 |
| | Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization | Q36365243 |
| | Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials | Q36466463 |
| | Differential metabolic effects of antipsychotic treatments | Q36548923 |
| | A review of atypical antipsychotic drugs versus conventional medication in schizophrenia | Q36573892 |
| | Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. | Q38399638 |
| | The economic burden of bipolar disease. | Q43606011 |
| | Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia | Q46969578 |
| | Intramuscular aripiprazole in the control of agitation | Q48468038 |
| | Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole | Q48472617 |
| | Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. | Q51910670 |
| | Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. | Q51912991 |
| | The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. | Q53260493 |
| | Amisulpride-induced hyperprolactinemia is reversible following discontinuation | Q80180010 |
| P433 | issue | 4 | |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 335-352 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | CNS Drugs | Q5013183 |
| P1476 | title | Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder | |
| P478 | volume | 22 | |